SLC5A2 and endothelial dysfunction: Furthermore, SGLT2 inhibition may also reduce BP by mechanisms unrelated to glucose lowering such as improved arterial stiffness [41] and endothelial dysfunction suggesting direct vascular effects [42, 43••], improved renal renin-angiotensin system activity [44] and reduced oxidative stress [45].